Innovating.works Conecta tu I+D

e-QuoL: e health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patien... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the int...
2023-12-13 - 2027-12-31 | Financiado

TIGER: Proof of Principle of the best in class therapeutic mRNA cancer vaccine CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-SC1-BHC-2018-2020 TIGER delivers proof of principle (PoP) in humans for a novel best-in-class therapeutic mRNA cancer vaccine platform optimized for intraveno...
2021-02-15 - 2025-07-31 | Financiado

QSPainRelief: Effective combinational treatment of chronic pain in individual patients by an innovative quantitat... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-SC1-BHC-2018-2020 Chronic pain is a complex disease suffered by about 20% of Europeans. Up to 60% of these patients do not experience adequate pain relief fro...
2019-12-13 - 2025-06-30 | Financiado

3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado

V.A. Cure: A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe s... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-MSCA-ITN-2018 Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and e...
2018-09-13 - 2023-02-28 | Financiado

IMI-PainCare: Improving the care of patients suffering from acute or chronic pain CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage There is a very high need for improving the management of pain. Acute and persistent pain of different origins represent a common medical, s...
2018-05-04 - 2023-03-31 | Financiado

IMMUNOSABR: Clinical proof of concept through a randomised phase II study a combination of immunotherapy and st... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-SC1-2016-2017 IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-m...
2016-12-12 - 2024-12-31 | Financiado

Microbes4U: Study of the therapeutic potential of an Akkermansia muciniphila based products in subjects with an... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: ERC-2015-PoC Overweight and obesity have reached worldwide epidemic level. Both overweight and obesity are characterized by comorbidities such as cardio-...
2016-06-27 - 2017-12-31 | Financiado

SPCCT: In Vivo Spectral Photon Counting CT Molecular Imaging in Cardio and Neuro Vascular Diseases CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-PHC-2014-2015 The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technolog...
2015-12-09 - 2021-06-30 | Financiado

ChiLTERN: Children s Liver Tumour European Research Network CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-PHC-2014-2015 Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in...
2015-12-07 - 2021-12-31 | Financiado

SEPCELL: Title of Proposal Restoring the immune system homeostasis and organ function in severe community ac... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-PHC-2014-2015 Sepsis is defined as a systemic inflammatory response to infection, while severe sepsis (SS) is a sepsis complicated by acute organ dysfunct...
2015-10-01 - 2022-04-30 | Financiado

BETA3_LVH: A multi center randomized placebo controlled trial of mirabegron a new beta3 adrenergic receptor a... CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-PHC-2014-2015 Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fra...
2015-04-15 - 2022-08-31 | Financiado

OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un H2020: H2020-PHC-2014-2015 Most older adults have multiple chronic diseases (multimorbidity) and multiple medications (polypharmacy). However, multimorbid patients are...
2015-04-07 - 2020-04-30 | Financiado

COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un FP6: Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of mult...
2015-01-01 - 2021-12-31 | Financiado

COMBACTE-NET: Combatting Bacterial Resistance in Europe CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un FP6: The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified...
2013-01-01 - 2021-02-28 | Financiado

COMBACTE-NET: Combatting Bacterial Resistance in Europe CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un FP7: The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified...
Financiado

COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe Molecules against Gram Negative Infections CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un FP7: Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of mult...
Financiado

SAGHE: Safety and Appropriateness of Growth hormone treatments in Europe CLINIQUES UNIVERSITAIRES SAINTLUC ASBL participó en un FP7: Recombinant growth hormone (GH) has been used since 1985. Current indications for GH use in children include GH deficiency and an increasing...
Financiado